$BBIO · BridgeBio Pharma, Inc.
BridgeBio reported Q3 2026 financial results with total revenues of $353.2M, up from $120.7M in Q3 2025, driven by $253.2M in U.S. Attruby net product revenue. Loss from operations narrowed sharply to $11.6M from $145.2M YoY, aided by a $75.0M Bayer milestone. The company holds $1.5B in cash and marketable securities and faces three near-term PDUFA catalysts: BBP-418 (Nov 27, 2026), oral infigratinib (Feb 4, 2027), and encaleret (May 8, 2027).
- Total Q3 revenue of $353.2M, up from $120.7M in Q3 2025, driven by Attruby U.S. net product revenue of $253.2M.
- Loss from operations narrowed to $11.6M from $145.2M YoY, aided by a one-time $75.0M BEYONTTRA sales milestone from Bayer.
- Cash, equivalents, and marketable securities stood at $1.5B as of September 30, 2026, funding all three launches and expansion indications.
- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date with Priority Review; no advisory committee meeting planned.
- Oral infigratinib (Feb 4, 2027) and encaleret (May 8, 2027) PDUFA dates both with Priority Review; field teams fully staffed.
Extended-hours trading shows BBIO at $69.90, down 1.17% from the regular close of $70.73, despite the strong revenue beat and narrowing losses — suggesting the market may have priced in the Attruby trajectory or is cautious on the three near-term PDUFA binary events.
BridgeBio is executing a rare biotech triple: a commercial launch ramping to near-profitability while three first-in-class therapies face FDA decisions within seven months, backed by $1.5B in cash.
BridgeBio is transitioning from a single-product ATTR-CM story to a multi-product rare-disease commercial platform, with three first-in-class or first-oral therapies approaching potential approval within seven months — a cadence rare in biotech.
Three PDUFA dates within seven months represent concentrated binary risk; any FDA rejection or delay on BBP-418, infigratinib, or encaleret would materially impact the launch pipeline. Preferred stock dividends and accretion of $26.3M in Q3 signal ongoing non-common-stock obligations.